Skip to main content
SpringerLink
Log in

Pembrolizumab: first drug available via early access scheme

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Merck & Co. KEYTRUDA(Rm) (pembrolizumab) is First Medicine to be Made Available to Patients Through U.K. Early Access to Medicines Scheme (EAMS) for Advanced Melanoma. Media Release : 10 Mar 2015. Available from: URL: http://www.merck.com

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pembrolizumab: first drug available via early access scheme. PharmacoEcon Outcomes News 724, 35 (2015). https://doi.org/10.1007/s40274-015-2013-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2013-1

Search

Navigation